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T
heprevalenceoftype2diabetescon-
tinuestogrow,anditispredictedthat,
unless effective prevention and con-
trol measures are implemented, the global
prevalence of the disease will exceed 366
million by 2030 (1). Type 2 diabetes is
associated with considerable morbidity,
excessmortality,andsubstantialcosts(2–
4). A recent statement issued by the
American Diabetes Association estimates
that in the U.S., the cost of diabetes in
2007 was $174 million. However, the ac-
tual national burden is likely to exceed
this ﬁgure because it does not include the
social costs of intangibles such as care
provided by nonpaid caregivers. Overall
costs are expected to increase further be-
cause of the projected rise in the propor-
tion of the population over the age of 65
years. Therefore, if successful, early inter-
vention to delay or prevent the develop-
ment of diabetes offers enormous
potential beneﬁt to individuals, health
care systems, and society.
Current diagnostic criteria for overt
diabetes include a fasting plasma glucose
concentration of 126 mg/dl or a 2-h
postchallenge plasma glucose concentra-
tion of 200 mg/dl during a 75-g oral
glucose tolerance test (5). The term “pre-
diabetes”hasrecentlybeenadoptedtode-
scribe conditions in which blood glucose
levels are elevated, but not above the
American Diabetes Association–deﬁned
level for diabetes; it includes the presence
of impaired fasting glucose (fasting
plasma glucose concentration of 100–
125 mg/dl) and/or impaired glucose tol-
erance (a 2-h post-challenge plasma
glucoseconcentrationof140–199mg/dl)
(6). Most individuals with pre-diabetes
will eventually develop overt diabetes. In
the American Diabetes Prevention Pro-
gram (DPP), the annual rate of develop-
ment of diabetes in subjects who had
impaired glucose tolerance or impaired
fasting glucose was 10% (7).
There is evidence that microvascular
disease typically associated with diabetes
is also observed in individuals with im-
paired glucose tolerance (8). A recent
analysis of data from the DPP showed
that 7.9% of subjects with impaired glu-
cose tolerance and 12.6% with newly
diagnosed diabetes had retinopathy char-
acteristic of diabetes (9). Moreover, con-
duction studies have shown that
neuropathy is present in 10–18% of pa-
tients with diabetes at the time of diagno-
sis, suggesting that peripheral nerve
injury may be occurring at lower levels of
glycemia (10). This hypothesis is sup-
ported by data from a cross-sectional
study in which the prevalence of neurop-
athy was found to be almost threefold
higher in subjects with impaired glucose
tolerance compared with normal control
subjects (11). A crude analysis of data
from the Framingham Heart Study
showed a 65% increase in risk of devel-
oping chronic kidney disease in subjects
withimpairedfastingglucoseorimpaired
glucosetolerance(comparedwithnormal
subjects), and a further analysis revealed
that this was accounted for largely by the
increase in vascular risk factors seen in
these subjects (12). The U.K. Prospective
Diabetes Study (13) demonstrated that
intensive glycemic control substantially
decreased the risk of microvascular com-
plications in patients with newly diag-
nosed type 2 diabetes, and it is likely that
similar treatment beneﬁts might be
gained in patients with pre-diabetes.
Thus, it is clear that pre-diabetes is
not a benign state and that early and ade-
quate intervention is indicated to prevent
the development of complications and
progression to overt diabetes. There is
now substantial evidence that progres-
sion to type 2 diabetes can be delayed or
prevented through lifestyle and pharma-
cologic interventions (14).
PHARMACOLOGIC
INTERVENTION IN
INDIVIDUALS AT HIGH
RISK OF DEVELOPING
DIABETES— A number of studies
havedocumentedbeneﬁcialeffectsoflife-
style intervention, including weight-
reducing diets and moderate-intensity
exercise, in preventing the development
of type 2 diabetes in high-risk subjects.
The Malmo ¨ study (15) was one of the ﬁrst
lifestyleinterventionstudiesandinvolved
men with impaired glucose tolerance and
early-stage type 2 diabetes. After a mean
follow-up of 6 years, glucose tolerance
wasnormalizedin50%ofsubjectswith
impaired glucose tolerance at the start of
the study, and 50% of subjects with di-
abetes reverted to a pre-diabetic state.
Similar ﬁndings were obtained in the Da
Qingstudy,whichexaminedtheeffectsof
diet and/or exercise in a Chinese popula-
tion with impaired glucose tolerance over
a 6-year follow-up period (16). All inter-
ventions were associated with a signiﬁ-
cant reduction in the risk of diabetes,
ranging from 36% in the diet-only group
to39%inthecombineddietplusexercise
group and 47% in the exercise-only
group. The results of these early studies
were subsequently conﬁrmed by two
well-designed studies: the Finnish Diabe-
tes Prevention Study and the DPP (7,17).
After 3 years of follow-up, in each of
these studies, there was a 58% relative
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Division of Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, Houston, Texas.
Corresponding author: Alan J. Garber, agarber@bcm.tmc.edu.
The publication of this supplement was made possible in part by unrestricted educational grants from Eli
Lilly,EthiconEndo-Surgery,GenerexBiotechnology,Hoffmann-LaRoche,Johnson&Johnson,LifeScan,
Medtronic, MSD, Novo Nordisk, Pﬁzer, sanoﬁ-aventis, and WorldWIDE.
DOI: 10.2337/dc09-S307
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
DIABETES PROGRESSION, PREVENTION, AND TREATMENT
S184 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 care.diabetesjournals.orgriskreductionintheincidenceofdiabetes
in the lifestyle intervention group com-
pared with control subjects.
The trials discussed above provide
convincing evidence that intensive life-
style interventions can reduce the risk of
progression from impaired glucose toler-
ancetoovertdiabetes.However,thereare
important reasons why similar success
rates cannot be anticipated in routine
clinical practice. First, the individuals
participating in the trials had access to
considerable support from health profes-
sionals.Forexample,boththeFinnishDi-
abetes Prevention Study and the DPP
involved multidisciplinary teams, includ-
ing a physician, dietitian, nurse, psychol-
ogist, and physiotherapist, providing
expertise in the areas of nutrition, behav-
ioral change, and physical activity. This
level of individual education and coach-
ingisnotlikelytobeavailableinareal-life
setting. Second, not all high-risk individ-
uals will be willing or able to accept and
implement the lifestyle changes that are
required to achieve meaningful health
beneﬁts. It is well known that the long-
term success rate of diet and lifestyle pro-
grams for weight reduction is very low.
Year on year, average population weight
and waist circumference continue to in-
crease, regardless of diets, TV public
awarenesscampaigns,andpersonaltrain-
ers. Indeed, given the dangers associated
with weight cycling and repeated failure,
it has been proposed that it is neither eth-
ical nor scientiﬁc to support the contin-
ued use of dieting for the management of
obesity (18). Although the effects of exer-
cise intervention for weight control ap-
pear to be more promising, there are only
minimal follow-up data for the ﬁrst cou-
pleofyearspostinterventionandvirtually
none after 5 years (18). The limited
amount of evidence that is available on
long-term follow-up of traditional diet
and exercise intervention studies for
weight loss suggests almost complete re-
lapse after 3–5 years (18). One might
think that patients with a potentially life-
threatening health condition would be
more likely to adopt and maintain a
healthier lifestyle, but this does not ap-
pear to be true. A recently published
studyhasshownthatdietaryqualitytends
to be poor, even in patients who have
been diagnosed with coronary heart dis-
ease within the past year (19), and in an-
other study in patients with coronary
heart disease, concordance with a recom-
mended cholesterol-lowering diet was
only moderate (20). In the latter study,
only one-third of the patients achieved
the recommended fat intake and only
one-quarter achieved the recommended
saturated fat intake. Moreover, concor-
dance was found to be unaffected by dis-
ease severity or previous myocardial
infarction and was slightly worse in pa-
tients who were obese or who had diabe-
tes. The long-term maintenance of
healthybehaviorsclearlypresentsamajor
challenge for health care providers and
their patients, and it seems unlikely that
dietary and lifestyle interventions will be
more successful in individuals with im-
paired glucose tolerance than in other pa-
tient populations. Therefore, there is a
need for safe and effective pharmacologic
therapiesthatcanbeusedincombination
with lifestyle modiﬁcation programs for
the prevention of diabetes (14).
Current clinical practice guidelines
advocate the use of metformin in combi-
nation with lifestyle modiﬁcation as ﬁrst-
line treatment for patients who have been
diagnosed with type 2 diabetes (21). Met-
formin has also been investigated for the
prevention of diabetes. The BIGPRO
(BIGuanides and the Prevention of the
Risk of Obesity) study was designed to
investigate whether metformin, used in
combination with lifestyle modiﬁcation,
couldmodifythemetabolicabnormalities
associated with insulin resistance in sub-
jectswithoutdiabetesbutwithcentralad-
iposity (high waist-to-hip ratio) (22).
Compared with placebo, metformin plus
lifestyle modiﬁcation was associated with
signiﬁcant weight loss, better mainte-
nance of fasting blood glucose, total and
LDL cholesterol levels, and a greater de-
crease of fasting plasma insulin concen-
tration. The authors concluded that
metformin would be a suitable candidate
for long-term intervention treatment for
thepreventionofdiabetes.Morerecently,
the DPP demonstrated that intervention
with metformin decreased the develop-
ment of diabetes in adults with impaired
glucose tolerance by 31% (7). However,
the combination of lifestyle modiﬁcation
plus metformin was not studied. Regard-
less of their diverse effects upon weight,
otherdrugsthathavebeeninvestigatedin
clinical trials for the prevention of diabe-
tes include acarbose, orlistat, troglita-
zone, rosiglitazone, and pioglitazone
(Table 1 shows a summary of key ade-
quately powered studies).
In the STOP-NIDDM (Study to Pre-
vent Non-Insulin-Dependent Diabetes
Mellitus) trial, treatment with the -glu-
cosidase inhibitor acarbose reduced pro-
gression to diabetes by 25% after 3.3
years (23). Although treatment with acar-
bose results in weight loss in some pa-
tients, the weight-reducing effect in this
trialwasnegligible.However,intheXEN-
DOS(XENicalinthePreventionofDiabe-
tes in Obese Subjects) study, the weight-
reducing agent orlistat (a gastrointestinal
lipase inhibitor) plus lifestyle changes re-
sulted in greater weight loss as well as a
greater reduction in the incidence of type
2 diabetes compared with lifestyle inter-
vention alone (24). A reduction in the in-
cidence of diabetes was only seen in
subjects with impaired glucose tolerance.
Treatment with the thiazolidinedione
troglitazone was included initially as one
of the arms of the DPP. However, this
treatment arm was discontinued after
about 1 year because of evidence of hep-
atotoxicity (25). In the TRIPOD (TRogli-
tazone In the Prevention Of Diabetes)
Table 1—Summary of key studies of pharmacologic interventions for the prevention of
diabetes
n Intervention
Duration
(years)
Relative risk
reduction (%)
DPP 2,151 Metformin 2.8 31
Knowler et al 2002; DPP Research
Group 2005
1,172 Troglitazone* 0.9 75
TRIPOD
Buchanan et al. 2002 236 Troglitazone 2.5 55
XENDOS
Torgerson et al. 2004 3,305 Orlistat 4.0 37
STOP-NIDDM
Chiasson et al. 2002 1,368 Acarbose 3.2 36
DREAM
DREAM Trial Investigators 2006 5,269 Rosiglitazone 3.0 60
*Treatment withdrawn after 1 year because of hepatotoxicity.
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gestational diabetes (a condition that is
known to predispose to subsequent de-
velopment of diabetes) received troglita-
zone and were followed up for an average
of 2.5 years before the drug was with-
drawnduetoadverseeffectsonliverfunc-
tion (26). In this study, treatment with
troglitazone was associated with a 55%
risk reduction of developing diabetes.
Women who completed the TRIPOD
studyweresubsequentlyinvitedtopartic-
ipate in the PIPOD (Pioglitazone In the
PreventionOfDiabetes)study,whichalso
showed relatively low rates of diabetes af-
ter3yearsoftreatmentwiththiscurrently
available thiazolidinedione agent (27).
The possibility of a class effect of thiazo-
lidinediones for diabetes prevention was
further supported by the results of the
DREAM (Diabetes REduction Assessment
with Ramipril and Rosiglitazone Medica-
tion) study, which showed a 60% reduc-
tion in the risk of diabetes or death in
subjects with pre-diabetes who were
treated with rosiglitazone (median dura-
tion of treatment was 3 years) (28).
Pharmacologic interventions that are
effective in the prevention of diabetes are
likely to act through a number of mecha-
nisms, in addition to weight control or
reduction. It has been shown that the on-
set of type 2 diabetes is preceded by a
marked deterioration of pancreatic -cell
function (29). An analysis of data from
autopsy ﬁles of subjects who were obese,
and with or without type 2 diabetes or
impaired fasting glucose, showed a curvi-
linear relationship between pancreatic
-cell mass and fasting blood glucose
concentrations (30). The development of
pharmacologic agents that can preserve
pancreatic -cell function is an exciting
area for current and future research.
Apreclinicalstudyindiabeticratshas
demonstrated that rosiglitazone prevents
thelossofpancreatic-cellmassbymain-
taining -cell proliferation and prevent-
ing net -cell death (31). Preservation of
pancreatic -cell function has also been
shown in clinical trials of thiazolidinedi-
one drugs. In the TRIPOD study, treat-
ment with troglitazone was associated
with preservation of -cell function in
Hispanic women who were at high risk of
developing diabetes (26), and similar ef-
fects were seen with pioglitazone in the
PIPOD study, providing support for a
class effect of thiazolidinedione drugs on
pancreatic -cell function (27).
ADOPT (A Diabetes Outcome Pro-
gression Trial) compared rosiglitazone,
metformin, and glyburide as initial treat-
ment for recently diagnosed type 2 diabe-
tes. The primary outcome was the time to
monotherapy failure. At 5 years, a lower
cumulative incidence of monotherapy
failure was seen with rosiglitazone (15%)
compared with metformin (21%) or gly-
buride (34%) (32). If the ﬁndings of the
TRIPODandPIPODstudiesdoindeedin-
dicate a class effect of the thiazolidinedio-
nes on pancreatic -cell function, it may
be that the sustained beneﬁt seen with
rosiglitazone in the ADOPT study was
due to preservation of pancreatic -cell
function. Newer classes of drugs, such as
the incretin mimetics and inhibitors of
dipeptidyl peptidase-4 activity, may also
provetobeeffectiveinpreservingpancre-
atic -cell function (33). The ability of
theseagentstodelayorpreventthedevel-
opment of diabetes in high-risk individu-
als may be conﬁrmed in future clinical
trials. Thus, the inability of lifestyle alone
to reverse the progressive -cell defect
that drives the appearance of type 2 dia-
betes may be reversed to a variable extent
by some pharmacologic therapies. It is
this ability that suggests that those thera-
pies will inevitably be included in diabe-
tes prevention programs.
The majority of health economic
studies published to date indicate that
currently available pharmacologic inter-
ventionsforthepreventionofdiabetesare
highly cost-effective (34). An analysis of
the total costs to the health system and
society in the DPP indicated that costs
were 25% higher for lifestyle interven-
tion compared with metformin ($4,603
metformin vs. $5,809 lifestyle) (35);
however, both types of intervention were
associated with only modest incremental
cost compared with placebo. A further
analysis of DPP data projected costs,
health outcomes, and cost-effectiveness
ofmetforminorlifestyleinterventionover
a lifetime compared with placebo (36).
The authors concluded that, compared
with placebo, both metformin and life-
style interventions provided clinically
meaningfulhealthbeneﬁtsatanattractive
cost. Both interventions were found to be
cost-effective in all age-groups, except for
metformin in participants aged 65
years.Thelong-termhealtheconomicim-
plications of implementing DPP-like
interventions in France, Germany, Swit-
zerland, U.K., and Australia have been
evaluated using economic modeling (37).
The results clearly illustrate that the cost-
effectiveness of such an intervention de-
pends on a number of variables related to
local constraints and that, to provide in-
formation that is relevant for the health
care payer, any program must be tailored
to the speciﬁc setting. As the clinical data
for new pharmacologic agents become
available, appropriate health economic
analyses will also be required.
CONCLUSIONS — The majority of
individuals with pre-diabetes (i.e., with
elevated fasting glucose levels and/or im-
pairedglucosetolerance)willgoontode-
velop overt diabetes, with its associated
complications and increased morbidity
andmortality.Moreover,themicrovascu-
lardiseasetypicallyassociatedwithdiabe-
tes is also observed in individuals with
impaired glucose tolerance. Therefore,
early and adequate intervention is indi-
catedtopreventthedevelopmentofcom-
plications and progression to diabetes. A
number of well-designed studies have
provided evidence that intensive lifestyle
intervention programs can signiﬁcantly
reduce the risk of progression from im-
pairedglucosetolerancetoovertdiabetes.
The implementation and maintenance of
the required behavioral changes in a “real
life”settingismorechallenging,however,
and similarly high success rates cannot be
anticipated in routine clinical practice.
The ﬁndings of published studies of the
use of lifestyle interventions for weight
loss and the reduction of cardiovascular
risk indicate that the majority of individ-
uals will fail to adhere to recommended
dietary interventions, and there is little
reason to suppose that concordance will
be any higher in patients with impaired
glucose tolerance. Therefore, there is a
need for safe and effective pharmacologic
therapiesthatcanbeusedincombination
with lifestyle modiﬁcation programs for
the prevention of diabetes.
Drugs that have been shown to re-
duce the relative risk of progression to
diabetes include metformin; the thiazo-
lidinediones troglitazone, rosiglitazone,
and pioglitazone; the -glucosidase in-
hibitor acarbose; and the gastrointestinal
lipase inhibitor orlistat. Pharmacologic
interventions that are effective in the pre-
vention of diabetes are likely to act
through a number of mechanisms, in ad-
dition to weight control or reduction. An
exciting area for current and future clini-
cal development is the use of drug treat-
mentsthatmaypreservepancreatic-cell
function.
Datafromanumberofclinicalstudies
have shown that the use of both pharma-
cologicandlifestyleinterventionstodelay
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ful, can result in substantial improve-
ments in health and economic outcomes,
thereby providing beneﬁts for patients,
healthcarepayers,andsocietyasawhole.
The risks and beneﬁts for the individual
patient should be considered when
choosing the most appropriate treatment
strategy, which should then be reviewed
and adjusted as needed to ensure the best
possible outcomes.
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